Reconstructive Surgery at Hysterectomy for Patients With Uterine Prolapse and Gynecologic Malignancy

Obstet Gynecol. 2023 Dec 1;142(6):1487-1490. doi: 10.1097/AOG.0000000000005405. Epub 2023 Oct 17.

Abstract

In this cross-sectional study examining 211,708 patients with a diagnosis of uterine prolapse who underwent hysterectomy between 2016 and 2019 identified in the Healthcare Cost and Utilization Project's Nationwide Ambulatory Surgery Sample, co-diagnosis of gynecologic malignancy was reported in 2,398 (1.1%) patients, and they were less likely to receive reconstructive surgery at hysterectomy (odds ratio [OR] 0.90, 95% CI 0.84-0.96). This absence of reconstructive surgery was most pronounced among patients with complete uterine prolapse and gynecologic malignancy (OR 0.68, 95% CI 0.57-0.81). The association was also consistent in coexisting gynecologic premalignancy (n=3,357 [1.6%]). In conclusion, this national-level assessment suggests that patients with uterine prolapse and coexisting gynecologic malignancy or premalignancy may be less likely to receive reconstructive surgery for pelvic floor dysfunction at hysterectomy.

MeSH terms

  • Cross-Sectional Studies
  • Female
  • Genital Neoplasms, Female* / surgery
  • Gynecologic Surgical Procedures
  • Humans
  • Hysterectomy
  • Pelvic Organ Prolapse* / complications
  • Pelvic Organ Prolapse* / surgery
  • Surgery, Plastic*
  • Uterine Prolapse* / complications
  • Uterine Prolapse* / surgery